Hemolysis in laboratory medicine – a US perspective
Dr. Cradic presents:
- Release Date: 28.11.2025
- Duration: 22 minutes
- Guest: Dr. Cradic
- Host: Director Global Medical & Clinical Affairs Ana-Maria Šimundić
- Introduction: Listen in as Dr. Cradic and Prof. Simundic explore the challenges of hemolysis detection in clinical labs, discussing automation, standardization, and the importance of quality assessment.
Timestamps for Episode 8
- 0:17 – Introducing Kendall Cradic
- 2:55 – Hemolysis definition & detection at CORPath
- 6:20 – Standardization of automated detection & cut-offs
- 8:06 – Heterogenity in acceptance criteria & decision limits
- 10:09 – How manufacturers can help
- 12:25 – Major causes & prevention of hemolysis
- 13:48 – How CORPath addresses these challenges
- 15:41 – Reporting hemolyzed samples
- 18:48 – Potential solutions 10 years from now
- 20:46 – Most memorable preanalytical moment
What You Can't Miss – In a Nutshell
Hemolysis detection methods vary widely
- Labs use visual, semi-automated, and automated approaches, causing inconsistency in hemolysis detection and reporting.
Prevention focuses on technique and transport
- Improving collection techniques and careful sample transport are vital to reducing hemolysis rates.
Rejecting a hemolyzed sample is never an easy decision
- Decisions to reject or report hemolyzed samples require careful judgment, balancing test validity and patient needs.
“The assays that we're running now compared to 20 years ago are using much less sample and the dilution factor is larger than it used to be and that in itself helps, because the assay has gotten so sensitive that we can do that dilution and get rid of interfering substances or get them reduced to where they're not interfering anymore and then get a quality result. ”
Get the latest from our podcast
Disclaimer & Shownotes
The guests interviewed in this podcast share their individual experiences with the use of our or comparable products and/or services. The opinions expressed are those of the interviewee and do not claim to represent the opinions or views of Greiner Bio-One. This information partially reflects the opinions of our customers and/or the experiences of individuals and does not claim to represent the opinions or views of Greiner Bio-One.
Products from Greiner Bio-One should only be used by appropriately trained medical professionals in accordance with the relevant instructions for use (IFU). A list of indications, contraindications, precautions, and warnings can be found in the instructions for use that accompany each product or can be downloaded from our website www.gbo.com (Download Center). For further information, please contact your local Greiner Bio-One distributor or visit our website.
All information is provided without guarantee despite careful processing. Liability, warranty, or guarantee of Greiner Bio-One GmbH is excluded. All rights, errors, and changes are reserved. Unless otherwise stated, Greiner Bio-One GmbH holds all copyrights and/or other (usage) rights in the present documents, especially to trademarks, such as the listed (word-image) marks, logos. Any use, reproduction, or other use of the rights of Greiner Bio-One GmbH is expressly prohibited.
Publisher and editor: Greiner Bio-One GmbH, Bad Haller Str. 32, 4550 Kremsmünster, Austria.
